“…In this paper, we developed a novel nano-biomaterial for selective photothermal therapy of HER2-positive breast cancers. We demonstrate that bovine serum albumin (BSA)-coated mini gold nanorods (GNRs) chemically conjugated with a HER2-specific designed ankyrin repeat protein, DARPin_9-29, selectively accumulate in HER2-positive xenograft tumors in mice and lead to a strong reduction in the tumor size when being illuminated with near-infrared light. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In the present study, two novel breast cancer cell lines designated as PC-B-142CA and PC-B-148CA were successfully established from HER2-positive and triple-negative (TN) breast cancer tissues. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In particular we investigated ER+ HER2- early breast cancer, considering its challenging risk stratification. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, anti-HER2 IgG-abundant plasma was screened from healthy donors to treat OSCC cells and to prepare for anti-HER2 intravenous immunoglobulin (IVIg). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…OBJECTIVE: The role of HMG-CoA reductase (HMGCR) in relation to prognostic and treatment predictive information of HER2 positive breast cancer has been newly explored. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Squamous cell carcinoma (SCC) of the breast is a rare malignancy that usually has a triple-negative phenotype and poor clinical outcomes. Because HER2-positive SCC of the breast is extremely rare, its clinicopathologic features are understudied, and the effects of neoadjuvant chemotherapy including anti-HER2-targeted therapy on the tumor are unclear, although treatment resistance was described in some reports. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2 Affibody and trastuzumab target different epitopes of the HER2 protein and do not compete. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Although immunotherapy has been used in the treatment of metastatic triple negative breast cancer (TNBC), its therapeutic influence on human epidermal growth factor receptor 2 (HER2)-positive subtype remains controversial. It is therefore imperative to find biomarkers that can predict the immune response in HER2+ BC. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Activation of the programmed cell death protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) signaling axis plays important roles in intrinsic or acquired resistance to human epidermal growth factor receptor 2 (HER2)-directed therapies in the clinic. Therefore, therapies simultaneously targeting both HER2 and PD-1/PD-L1 signaling pathways are of great significance. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Approximate 25% HER2-positive (HER2(+)) breast cancer (BC) patients treated with trastuzumab recurred rapidly. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…HER2 is regarded as negative when the IHC result is 0/1+ without the addition of FISH. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this study, Tra-TTR-A, a new type of near-infrared fluorescent nanoprobe that targets HER2-positive breast cancer, was successfully synthesized. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: According to 2018 ASCO/CAP guideline, HER2 FISH-equivocal breast cancers will be categorized as HER2 negative except those with IHC 3+. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The κ-statistic was 0.3624 for the resulting luminal, HER2, and TN subtypes. The probability of 5-year RFS was 0.78 for the luminal subtype versus 0.77 for HER2 and 0.51 for TN, when determined by IHC (P=0.007); and 0.80, 0.71, and 0.61, respectively, when determined by the RT-PCR method (P=0.008). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We conducted a retrospective study to compare the efficacy and safety of nab-paclitaxel with those of docetaxel as neoadjuvant regimens for HER2-negative breast cancer. METHODS: In this retrospective analysis, a total of 159 HER2-negative breast cancer patients who had undergone operation after NAC were consecutively analyzed from May 2016 to April 2018. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…For HER2-equivocal cases, the HR was 1.59 (95% CI, 0.40–6.34; P=0.50) compared with HER2-negative cases. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Afatinib, a member of irreversible HER family inhibitor, has been investigated by a number of literatures, yet whose therapeutic efficiency remains uncertain in NSCLC with HER2 mutation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Previous studies have evaluated the effect of human epidermal growth factor receptor 2 (HER-2) expression on the metastasis of patients with osteosarcoma (OS) while the results remain conflicting. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso